Corporate Banner
Satellite Banner
Metabolomics & Lipidomics
Scientific Community
Become a Member | Sign in
Scientific News
Gut Microbes Signal to the Brain When They're Full
Don't have room for dessert? The bacteria in your gut may be telling you something.
Turning up the Tap on Microbes Leads to Better Protein Patenting
Mining millions of proteins could become faster and easier with a new technique that may also transform the enzyme-catalyst industry, according to University of California, Davis, researchers.
Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers
New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health.
Cancer-Fighting Tomato Component Traced
The metabolic pathway associated with lycopene, the bioactive red pigment found in tomatoes, has been traced by researchers at the University of Illinois.
Circadian Clock Controls Insulin and Blood Sugar in Pancreas
Map of thousands of genes suggests new therapeutic targets for diabetes.
Cellular Stress Process Identified in Cardiovascular Disease
Combining the investigative tools of genetics, transcriptomics, epigenetics and metabolomics, a Duke Medicine research team has identified a new molecular pathway involved in heart attacks and death from heart disease.
Predicting Adverse Drug Reactions with Higher Confidence
A new integrated computational method helps predicting adverse drug reaction—which are often lethal—more reliably than with traditional computing methods.
A New Way to Starve Lung Cancer?
Metabolic alterations in lung cancer may open new avenues for treating the disease.
Evidence of How Incurable Cancer Develops
Researchers in the West Midlands have made a breakthrough in explaining how an incurable type of blood cancer develops from an often symptomless prior blood disorder.
Building a Better Liposome
Computational models suggest new design for nanoparticles used in targeted drug delivery.

Multiplexed Diagnostics 2010
Bookmark and Share

Published: May 2010
Pages: 572
Published by: BioPerspectives

The multiplexed diagnostics market has grown rapidly and generated sales of approximately $2.4 billon in 2009, but is now balanced on multiple tipping points. Will the FDA finally release the updated IVDMIA guidelines? If so, will the FDA close the CLIA loophole and/or will the FDA require 510(k) approvals for all multivariate diagnostics? Will Genomic Health and Agendia be able to maintain high prices for their flagship tests amidst growing competition? How many new tests will reach the market in 2010? Does the inability of Genomic Health’s new colon cancer diagnostic to predict response to chemotherapy indicate ongoing challenges in developing new multivariate diagnostics or is this an isolated example? Will growing competition lead to market confusion? In situations with similar tests, how will physicians and payers decide? Will they want to see more prospective clinical trials? Will prospective clinical trials be more attractive due to the experience of XDx? As multiplexed diagnostics become more established, will physicians and payers begin to actively seek these new tests to increase the efficiency of healthcare? Will changes in healthcare policies, especially in the US, be a net positive because of the expanded use of tests (for aging and expanding populations) or a net negative because of cost controls? Will new multiplexing technologies, such as MagPix from Luminex and BeadXpress from Illumina, create another shift in the market or are diagnostics laboratories becoming entrenched with current methods? Will new biomarkers, such as microRNA and methylated DNA, be more powerful than gene expression levels? For genetic tests, how far will multiplexing go? Is Counsyl’s combination of 100 genetic tests only the beginning? If so, will the increasing complexity of genetic tests usher in the era of diagnostic DNA sequencing?

On the whole, the multiplexed diagnostics market is expected to tip in favor of continued rapid growth, reaching almost $5.8 billion in 2015, according to a new report, Multiplexed Diagnostics 2010, published by Select Biosciences and written by BioPerspectives and Bachmann Consulting. This report explains the unmet needs, trends, regulations, reimbursement, competition, technologies and business strategies. This 572-page report includes a survey of more than 400 respondents, interviews with 12 experts, a detailed database of more than 190 commercial multiplexed diagnostics and a two-tiered quantitative worldwide market model. In addition, the report comes with one hour of consulting (in the form of a conference call) with one of the authors, Dr. Steven Bodovitz, Principal of BioPerspectives, or Dr. Jutta Bachmann, CEO of Bachmann Consulting.

Related Content

Technology Networks Presents Poster Award at Advances in Metabolic Profiling Conference
The publishers of sponsored the poster award at Select Biosciences 2nd annual AMP conference.
Monday, October 30, 2006
Call for Papers - European Biomarkers Summit
Experts from both academia and commerce are invited to present timely information from current research through to commercial implementation of new technologies.
Thursday, February 09, 2006
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos